New Pathway for Tissue-Type Plasminogen Activator Regulation

New pathway for tissue-type plasminogen activator regulation.

C irculating levels of tissue-type plasminogen activator (tPA) are correlated with risk of incident cardiovascu-lar disease (CVD) among individuals with clinical athero-sclerosis and in the general population, but a simple causal interpretation of this association belies epidemiological and regulatory complexity (eg, Ref. 1 and references therein). tPA, encoded by the PLAT gene, is an enzyme th...

Optimizing refolding condition for recombinant tissue plasminogen activator

Low molecular size additives such as L-arginine and the redox compounds have been used both in the culturemedium and in vitro refolding to increase recombinant proteins production. Additives increase proteinrefolding and yield of active proteins by suppressing aggregate formation or enhancing refolding process.In this work, a comparative study was performed on refolding of rec...

Human tissue-type plasminogen activator.

Tissue-type plasminogen activator (t-PA ) plays an important role in the removal of intravascular fibrin deposits and has several physiological roles and pathological activities in the brain. Its production by many other cell types suggests that t-PA has additional functions outside the vascular and central nervous system. Activity of t-PA is regulated at the level of its gene transcription, it...

Tissue-type plasminogen activator release: new frontiers in endothelial function.

Tissue-type plasminogen activator (t-PA) is a pivotal enzyme in the mammalian fibrinolytic system. It exerts its action by converting the zymogen plasminogen into the proteolytically active serine protease plasmin, which, in turn, degrades fibrin clots. Because of its affinity for fibrin, t-PA is the prototypic fibrin-specific plasminogen activator (1). This specificity and its lack of antigeni...

Deficiency Exacerbates Arthritis Tissue-Type Plasminogen Activator